Effectiveness of aluminum hydroxide timing administration in relation to meals in controling hyperphosphatemia in dialysis patients

International Journal of Artificial Organs

Volumn 28, Issue 8, 2005, Pages 803-807

  Katopodis, K P ^a   Andrikos, E ^a   Pappas, M ^a   Siamopoulos, Kostas C ^a,b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Aluminum hydroxide; Hemodialysis; Hyperphosphatemia; Meals

Indexed keywords

ALUMINUM HYDROXIDE; BINDERS; HEMODIALYZERS; INDIUM COMPOUNDS; TIMING CIRCUITS;

HAEMODIALYSIS; HEMODIALYSIS PATIENT; HYPERPHOSPHATEMIA; MEAL; PHOSPHATE BINDERS; PHOSPHATE SALTS;

DIALYSIS;

ALUMINUM HYDROXIDE; PHOSPHATE; PHOSPHATE BINDING AGENT;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE CONTROL; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEAL; PHOSPHATE BLOOD LEVEL; PRIMARY PREVENTION; STATISTICAL SIGNIFICANCE;

EID: 27544433439     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880502800806     Document Type: Article

References (26)

1. Ritz E, Matthias S, Seidel A, Reichel H, Szabo A, Horl WH. Disturbed calcium metabolism in renal failure. Pathogenesis and therapeutic strategies. Kidney Int 1992; 42 (suppl 38): S37-42.
2. Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998; 53: 1399-404.
3. Zucchelli P, Santoro A. Inorganic phosphate removal during different dialytic procedures. Int J Artif Organs 1987; 10: 137-8.
4. Abrams DE, Silcott RB, Terry R, Berne TV, Barbour BH. Antacid induction of phosphate depletion syndrome in renal failure. West J Med 1974; 120: 157-60.
5. Consensus conference: Diagnosis and treatment of aluminum overload in end - stage renal failure patients. Nephrol Dial Transplant 1993; 8 (suppl 1): S1-4.
6. Salusky IB, Foley J, Nelson P, Goodman WG. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 1991; 324: 527-31.
7. Schiller LR, Santa Ana CA, Sheikh MS, Emmett M, Fordtran JS. Effect of the time of administration of Ca acetate on phosphorus in uremia. N Engl J Med 1989; 320: 1110-3.
8. Coburn JW, Salusky IB. Control of serum phosphorus in uremia. N Engl J Med 1989; 320: 1140-2.
9. Delmez JA, Tindira CA, Windus DW, Norweed KY, Giles KS, Nighswander TL, Slatopolsky E. Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 1992; 3: 96-102.
10. Fournier A, Moriniere PH, Sebert JL, Dkhissi H, Atik A, Leflon P, Renaud H, Gueris J, Gregoire I, Idrissi A, Garabedian M. Calcium carbonate, an aluminum - free agent for control of hyperphosphatemia, hypocalcemia, and hyperpharathyroidism in uremia. Kidney Int 1986; 18 (suppl): S114-9.
11. Harvey SC. Gastric antacids and digestants. In: Giman AG, Goodman LS, Gilman A, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 6th ed. New York: Macmillan, 1980: 988-1001.
12. Raman A. The calcium fractions of normal serum. Clin Biochem 1971; 4: 141-6.
13. Daugirdas JT. Second generation logarithmic estimates of single - pool variable volume Kt/V: An analysis of error. J Am Soc Nephrol 1993; 4: 1206-13.
14. Garred LJ, Barichello DL, Canaud BC, McCready WG. Simple equations for protein catabolic rate determination from pre dialysis and post dialysis blood urea nitrogen. ASAIO J 1995; 41: 889-95.
15. Cross HS, Debiec H, Peterlik M. Mechanism and regulation of intestinal phosphate absorption. Miner Electrolyte Metab 1990; 16: 115-24.
16. Graziani G, Como G, Badalamenti S, Finazzi S, Malesci A, Gallieni M, Brancaccio D, Ponticelli C. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant 1995; 10: 1376-80.
17. Van Riemsdijk WH, Lyklema J. The reaction of phosphate with aluminm hydroxide in relation with phosphate - binding in soils. Colloid and Surfaces 1980; 1: 33-44.
18. Larson EA, Ash SR, Hem SL. Phosphate binding gels: Balancing phosphate adsorption and aluminum toxicity. Kidney Int 1986; 29: 1131-5.
19. 3] beyond the adsorption maximum. J Colloid Interface Sci 1980; 76: 55-66.
20. Sheikh MS, Maguire JA, Emmatt M, Santa Ana CA, Nicra MJ, Shiller LR, Fordtran JS. Reduction of dietary phosphate absorption by phosphorus binders. A theoretical, in vitro and in vivo study. J Clin Invest 1989; 83: 66-73.
21. Balasa RW, Murray RL, Kondelis NP, Bischel MD. Phosphate - binding properties and electrolyte content of aluminum hydroxide antacids. Nephron 1987; 45: 16-21.
22. Merki HS, Witzel L, Kaufmann D, Kempf M, Muessing V, Neumann J, Scheurle E, Roehmel J, Walt RP. Assessment of intragastric acidity in man: Modern aspects, reproductibility of intragastric pH - monitoring, and pharmacodynamic results obtained with H2-receptor antagonist. Scand J Gastroenterol 1988; 23 (suppl 146): S124-50.
23. Tan CC, Harden PN, Rodger RS, Rowe PA, Spooner RJ, Junor BJR, Briggs ID. Ranitidine reduces phosphate binding in dialysis patients receiving calcium carbonate. Nephrol Dial Transplant 1996; 11: 851-3.
24. Czapla K, Rodger RSC, Halls DJ, Muralikrishna GS, Macdougall AI, Fell GS. Ranitidine reduces aluminum tocicity in patients with renal failure. Nephrol Dial Transplant 1992; 7: 1246-8.
25. Hardy P, Sechet A, Hottelart C, Oprisiu R, Abighamen O, Said S, Rasombololona M, Brazier M, Moriniere P, Achard J-M, Pruna A, Fournier A. Inhibition of gastric secretion by omeprazole and efficacy of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Int J Artif Organs 1998; 22: 569-73.
26. Osler P, Raniga P, Farrington K. Effect of omeprazole on the phosphate - binding capacity of calcium carbonate. Nephron 1995; 69: 89-90.